CD117 immunoreactivity in high-grade neuroendocrine tumors of the lung: A comparative study of 39 large-cell neuroendocrine carcinomas and 27 surgically resected small-cell carcinomas

Giuseppe Pelosi, Michele Masullo, Maria Elena Leon, Giulia Veronesi, Lorenzo Spaggiari, Felice Pasini, Angelica Sonzogni, Antonio Iannucci, Enrica Bresaola, Giuseppe Viale

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Little is known about CD117 prevalence and clinicopathological implications in pulmonary large-cell neuroendocrine carcinoma. We studied CD117 immunoreactivity in surgical specimens from 39 large-cell neuroendocrine carcinomas of stages I-III and 27 limited-disease small-cell carcinomas, 56 typical and atypical carcinoids of the lung, and 10 neuroendocrine tumorlets, including the membrane and cytoplasmic immunostaining patterns. Membrane CD117 immunoreactivity in 5% or more tumor cells was documented in 30 (77%) large-cell neuroendocrine carcinomas and 18 (67%) small-cell carcinomas and 4 (7%) carcinoids, whereas cytoplasmic labeling was seen in 17 (44%) large-cell neuroendocrine carcinomas, 19 (70%) small-cell carcinomas, and 3 (5%) carcinoids. None of the neuroendocrine cells of the normal bronchial epithelium and of 10 tumorlets showed any CD117 immunoreactivity. Cytoplasmic immunostaining was more prevalent in small-cell carcinomas, whereas membrane labeling did not differ between the two types of high-grade carcinomas. Downregulation of CD117 by neoadjuvant chemotherapy was seen in large-cell neuroendocrine carcinomas but not small-cell carcinomas. Multiple linear regression analysis demonstrated a marginal association between cytoplasmic CD117 immunoreactivity and regional lymph node metastasis in small-cell carcinomas but not large-cell neuroendocrine carcinomas. There was no association between CD117 immunoreactivity and survival in either small-cell carcinoma or large-cell neuroendocrine carcinoma patients.

Original languageEnglish
Pages (from-to)449-455
Number of pages7
JournalVirchows Archiv
Volume445
Issue number5
DOIs
Publication statusPublished - Nov 2004

Fingerprint

Neuroendocrine Carcinoma
Large Cell Carcinoma
Small Cell Carcinoma
Neuroendocrine Tumors
Lung
Carcinoid Tumor
Neuroendocrine Cells
Membranes
Linear Models
Down-Regulation
Epithelium
Lymph Nodes
Regression Analysis
Cell Membrane
Neoplasm Metastasis
Carcinoma
Drug Therapy
Survival

Keywords

  • Carcinoma
  • CD117
  • Large-cell
  • Neuroendocrine
  • Small-cell

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

@article{6d6013dc8e124de0be44af0e3e4dbbd0,
title = "CD117 immunoreactivity in high-grade neuroendocrine tumors of the lung: A comparative study of 39 large-cell neuroendocrine carcinomas and 27 surgically resected small-cell carcinomas",
abstract = "Little is known about CD117 prevalence and clinicopathological implications in pulmonary large-cell neuroendocrine carcinoma. We studied CD117 immunoreactivity in surgical specimens from 39 large-cell neuroendocrine carcinomas of stages I-III and 27 limited-disease small-cell carcinomas, 56 typical and atypical carcinoids of the lung, and 10 neuroendocrine tumorlets, including the membrane and cytoplasmic immunostaining patterns. Membrane CD117 immunoreactivity in 5{\%} or more tumor cells was documented in 30 (77{\%}) large-cell neuroendocrine carcinomas and 18 (67{\%}) small-cell carcinomas and 4 (7{\%}) carcinoids, whereas cytoplasmic labeling was seen in 17 (44{\%}) large-cell neuroendocrine carcinomas, 19 (70{\%}) small-cell carcinomas, and 3 (5{\%}) carcinoids. None of the neuroendocrine cells of the normal bronchial epithelium and of 10 tumorlets showed any CD117 immunoreactivity. Cytoplasmic immunostaining was more prevalent in small-cell carcinomas, whereas membrane labeling did not differ between the two types of high-grade carcinomas. Downregulation of CD117 by neoadjuvant chemotherapy was seen in large-cell neuroendocrine carcinomas but not small-cell carcinomas. Multiple linear regression analysis demonstrated a marginal association between cytoplasmic CD117 immunoreactivity and regional lymph node metastasis in small-cell carcinomas but not large-cell neuroendocrine carcinomas. There was no association between CD117 immunoreactivity and survival in either small-cell carcinoma or large-cell neuroendocrine carcinoma patients.",
keywords = "Carcinoma, CD117, Large-cell, Neuroendocrine, Small-cell",
author = "Giuseppe Pelosi and Michele Masullo and Leon, {Maria Elena} and Giulia Veronesi and Lorenzo Spaggiari and Felice Pasini and Angelica Sonzogni and Antonio Iannucci and Enrica Bresaola and Giuseppe Viale",
year = "2004",
month = "11",
doi = "10.1007/s00428-004-1106-1",
language = "English",
volume = "445",
pages = "449--455",
journal = "Virchows Archiv - A Pathological Anatomy and Histopathology",
issn = "0945-6317",
publisher = "Springer Verlag",
number = "5",

}

TY - JOUR

T1 - CD117 immunoreactivity in high-grade neuroendocrine tumors of the lung

T2 - A comparative study of 39 large-cell neuroendocrine carcinomas and 27 surgically resected small-cell carcinomas

AU - Pelosi, Giuseppe

AU - Masullo, Michele

AU - Leon, Maria Elena

AU - Veronesi, Giulia

AU - Spaggiari, Lorenzo

AU - Pasini, Felice

AU - Sonzogni, Angelica

AU - Iannucci, Antonio

AU - Bresaola, Enrica

AU - Viale, Giuseppe

PY - 2004/11

Y1 - 2004/11

N2 - Little is known about CD117 prevalence and clinicopathological implications in pulmonary large-cell neuroendocrine carcinoma. We studied CD117 immunoreactivity in surgical specimens from 39 large-cell neuroendocrine carcinomas of stages I-III and 27 limited-disease small-cell carcinomas, 56 typical and atypical carcinoids of the lung, and 10 neuroendocrine tumorlets, including the membrane and cytoplasmic immunostaining patterns. Membrane CD117 immunoreactivity in 5% or more tumor cells was documented in 30 (77%) large-cell neuroendocrine carcinomas and 18 (67%) small-cell carcinomas and 4 (7%) carcinoids, whereas cytoplasmic labeling was seen in 17 (44%) large-cell neuroendocrine carcinomas, 19 (70%) small-cell carcinomas, and 3 (5%) carcinoids. None of the neuroendocrine cells of the normal bronchial epithelium and of 10 tumorlets showed any CD117 immunoreactivity. Cytoplasmic immunostaining was more prevalent in small-cell carcinomas, whereas membrane labeling did not differ between the two types of high-grade carcinomas. Downregulation of CD117 by neoadjuvant chemotherapy was seen in large-cell neuroendocrine carcinomas but not small-cell carcinomas. Multiple linear regression analysis demonstrated a marginal association between cytoplasmic CD117 immunoreactivity and regional lymph node metastasis in small-cell carcinomas but not large-cell neuroendocrine carcinomas. There was no association between CD117 immunoreactivity and survival in either small-cell carcinoma or large-cell neuroendocrine carcinoma patients.

AB - Little is known about CD117 prevalence and clinicopathological implications in pulmonary large-cell neuroendocrine carcinoma. We studied CD117 immunoreactivity in surgical specimens from 39 large-cell neuroendocrine carcinomas of stages I-III and 27 limited-disease small-cell carcinomas, 56 typical and atypical carcinoids of the lung, and 10 neuroendocrine tumorlets, including the membrane and cytoplasmic immunostaining patterns. Membrane CD117 immunoreactivity in 5% or more tumor cells was documented in 30 (77%) large-cell neuroendocrine carcinomas and 18 (67%) small-cell carcinomas and 4 (7%) carcinoids, whereas cytoplasmic labeling was seen in 17 (44%) large-cell neuroendocrine carcinomas, 19 (70%) small-cell carcinomas, and 3 (5%) carcinoids. None of the neuroendocrine cells of the normal bronchial epithelium and of 10 tumorlets showed any CD117 immunoreactivity. Cytoplasmic immunostaining was more prevalent in small-cell carcinomas, whereas membrane labeling did not differ between the two types of high-grade carcinomas. Downregulation of CD117 by neoadjuvant chemotherapy was seen in large-cell neuroendocrine carcinomas but not small-cell carcinomas. Multiple linear regression analysis demonstrated a marginal association between cytoplasmic CD117 immunoreactivity and regional lymph node metastasis in small-cell carcinomas but not large-cell neuroendocrine carcinomas. There was no association between CD117 immunoreactivity and survival in either small-cell carcinoma or large-cell neuroendocrine carcinoma patients.

KW - Carcinoma

KW - CD117

KW - Large-cell

KW - Neuroendocrine

KW - Small-cell

UR - http://www.scopus.com/inward/record.url?scp=9944263021&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=9944263021&partnerID=8YFLogxK

U2 - 10.1007/s00428-004-1106-1

DO - 10.1007/s00428-004-1106-1

M3 - Article

C2 - 15375659

AN - SCOPUS:9944263021

VL - 445

SP - 449

EP - 455

JO - Virchows Archiv - A Pathological Anatomy and Histopathology

JF - Virchows Archiv - A Pathological Anatomy and Histopathology

SN - 0945-6317

IS - 5

ER -